Celularity Incorporated: Clinical Trials

5 trials sponsored by Celularity Incorporated, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 terminated. 5 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Terminated 5
Phase 12Terminated 2

Follow Celularity Incorporated: new trials by email

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
CYNK-101, Pembrolizumab, Trastuzumab - Metastatic HER2 Positive Gastroesophageal Junction Cancer
Phase 1 / Phase 2TerminatedCelularity Incorporated12022-04-142024-12-12
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
CYNK-001 - Coronavirus, Coronavirus Infection
Phase 1 / Phase 2TerminatedCelularity Incorporated72020-09-022026-06-26
Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.
PDA-002, Placebo - Peripheral Arterial Disease, Diabetic Foot
Phase 2TerminatedCelularity Incorporated1592014-10-232026-06-12
Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke
Human Placenta-Derived Cells PDA001- (cenplacel-L), Placebo - Stroke, Acute, Middle Cerebral Artery Stroke
Phase 2TerminatedCelularity Incorporated442011-03-012018-03-01
Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis
PDA001, Vehicle Controlled Placebo - Rheumatoid Arthritis
Phase 2TerminatedCelularity Incorporated262010-12-012020-07-22

Conditions studied

Arthritis, Rheumatoid (1)  ·  COVID-19 (1)  ·  Coronaviridae Infections (1)  ·  Coronavirus Infections (1)  ·  Diabetic Foot (1)  ·  Immune System Diseases (1)  ·  Infarction, Middle Cerebral Artery (1)  ·  Infarction, Posterior Cerebral Artery (1)  ·  Lung Diseases (1)  ·  Nidovirales Infections (1)  ·  Peripheral Arterial Disease (1)  ·  Pneumonia (1)  ·  Pneumonia, Viral (1)  ·  RNA Virus Infections (1)  ·  Respiratory Tract Diseases (1)

Interventions

Cyclophosphamide (1)  ·  Mesna (1)  ·  Trastuzumab (1)  ·  aldesleukin (1)  ·  fludarabine (1)  ·  fludarabine phosphate (1)  ·  pembrolizumab (1)

Countries

United States (5)

Top investigators

Adrian Kilcoyne, MD (1)  ·  Corey Casper, MD MPH (1)  ·  Monica E Luchi, MD (1)  ·  Sharmila Koppisetti, MD (1)  ·  Solveig Ericson, MD (1)

Results publications

PMID 41077558